Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial
Articolo
Data di Pubblicazione:
2014
Abstract:
Serelaxin is effective in relieving dyspnoea and improving multiple outcomes in acute heart failure (AHF). Many AHF patients have preserved ejection fraction (HFpEF). Given the lack of evidence-based therapies in this population, we evaluated the effects of serelaxin according to EF in RELAX-AHF trial.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Acute heart failure; Diastolic heart failure; Dyspnoea; Heart failure with preserved left ventricular ejection fraction; Relaxin; Serelaxin; Aged; Analysis of Variance; Biological Markers; Cardiotonic Agents; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Length of Stay; Male; Recombinant Proteins; Relaxin; Stroke Volume; Treatment Outcome; Ventricular Function, Left
Elenco autori:
Filippatos, G; Teerlink, Jr; Farmakis, D; Cotter, G; Davison, Ba; Felker, Gm; Greenberg, Bh; Hua, T; Ponikowski, P; Severin, T; Unemori, E; Voors, Aa; Metra, M
Link alla scheda completa:
Pubblicato in: